Pharmacotherapy of Diabetic Foot Ulcers

Journal of Pharmacy Practice

Volumn 17, Issue 1, 2004, Pages 66-74

  Smith, Cuitis L ^a,b  

^a Claire Dart Stroke Center Sparrow Hospital   (United States)

^b FERRIS STATE UNIVERSITY   (United States)

Author keywords

Antibiotics; Diabetes; Foot; Infection; Ulcers

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BECAPLERMIN; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GROWTH FACTOR; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; NAFCILLIN; OFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEUROPATHY; DISEASE CLASSIFICATION; FOOT ULCER; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; OUTPATIENT; REVIEW; RISK FACTOR; UNITED STATES;

EID: 1642539075     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190003261311     Document Type: Review

References (47)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2000. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2002.
2. O'Brien IAD, Corrall RJM. Epidemiology of diabetes and its complications. N Engl J Med. 1988;318:1619-1620.
3. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377-384.
4. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382-387.
5. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998;21:1071-1075.
6. de Sonnaville JJ, Colly LP, Wijkel D, Heine RJ. The prevalence and determinants of foot ulceration in type II diabetic patients in a primary health care setting. Diabetes Res Clin Pract. 1997;35:149-156.
7. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg. 1998;176(suppl 2A):5S-10S.
8. Laing P. The development and complications of diabetic foot ulcers. Am J Surg. 1998;176(suppl 2A):11S-19S.
9. Sumpio BE. Foot ulcers. N Engl J Med. 2000;343:787-793.
10. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. 2003;361:1545-1551.
11. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25:1318-1326.
12. Lipsky BA, Pecoraro RE, Chen MS, Koepsell TD. Factors affecting staphylococcal colonization among NIDDM outpatients. Diabetes Care. 1987;10:483-486.
13. Armstrong DG, Peters EJG. Classification of wounds of the diabetic foot. Curr Diab Rep. 2001;1:233-238.
14. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998;21:855-859.
15. Grayson ML. Diabetic foot infections. Antimicrobial therapy. Infect Dis Clin N Amer. 1995;9:143-161.
16. Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med. 1986;146:1935-1940.
17. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. 1990;150:790-797.
18. Louie TJ, Bartlett JG, Tally FP, Gorbach SL. Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med. 1976;85:461-463.
19. Jones EW, Edwards R, Finch R, Jeffcoate WJ. A microbiological study of diabetic foot lesions. Diabet Med. 1985;2:213-215.
20. El-Tahawy AT. Bacteriology of diabetic foot infections. Saudi Med J. 2000;21:344-347.
21. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18:683-693.
22. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med. 2003;20:159-161.
23. Fejfarova V, Jirkovska A, Skibova J, Petkov V. Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome. Vnitr Lek. 2002;48:302-306.
24. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994;331:854-860.
25. Calhoun JH, Overgaard KA, Stevens CM, Dowling JPF, Mader JT. Diabetic foot ulcers and infections: current concepts. Adv Skin Wound Care. 2002;15:31-45.
26. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis. 1997;24:643-648.
27. Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA. 1991;266:1246-1251.
28. Diamantopoulos EJ, Haritos D, Yfandi G, et al. Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes. 1998;106:346-352.
29. Calandra GB, Raupp W, Brown KR. Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics. Scand J Infect Dis. 1987;52(suppl):15-19.
30. Akova M, Ozcebe O, Gullu I, et al. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. J Chemother. 1996;8:284-289.
31. Zeillemaker AM, Veldkamp KE, van Kraaij MG, et al. Piperacillin/tazobactam therapy for diabetic foot infection. Foot Ankle Int. 1998;19:169-172.
32. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med. 1997;336:999-1007.
33. Bamberger DM, Daus GP, Gerding DN. Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med. 1987;83:653-660.
34. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vancher J, Lew PD. Outcome of diabetic foot infections treated conservatively. Arch Intern Med. 1999;159:851-856.
35. Henry G, Garner WL. Inflammatory mediators in wound healing. Surg Clin N Am. 2003;83:483-507.
36. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg. 1995;21:71-78.
37. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled doubleblind study. Diabetes Care. 1998;21:822-827.
38. Ortho-McNeil Pharmaceutical, Inc. Regranex (becaplermin) [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; August 2003.
39. Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colin S, Paz-Janeiro JL, Alvarado-Ruiz R, Garcia-Salazar R. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study. Adv Ther. 2000;17:184-189.
40. Embil JM, Papp K, Sibbald G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen. 2000;8:162-168.
41. Wieman TJ, Becaplermin Gel Studies Group. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Am J Surg. 1998;176(suppl 2A):74S-79S.
42. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg. 2002;28(8):698-703.
43. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24:290-295.
44. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26:1701-1705.
45. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet. 1997;350:855-859.
46. Yonem A, Cakir B, Guler S, Azal O, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab. 2001;3:332-337.
47. Kastenbauer T, Hornlein B, Sokol G, Irsigler K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia. 2003;46:27-30.